CGTX vs. JATT, ATHA, DTIL, GRTS, TIL, CVM, PASG, ELUT, ATRA, and PLX
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include JATT Acquisition (JATT), Athira Pharma (ATHA), Precision BioSciences (DTIL), Gritstone bio (GRTS), Instil Bio (TIL), CEL-SCI (CVM), Passage Bio (PASG), Elutia (ELUT), Atara Biotherapeutics (ATRA), and Protalix BioTherapeutics (PLX). These companies are all part of the "biological products, except diagnostic" industry.
Cognition Therapeutics (NASDAQ:CGTX) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
JATT Acquisition's return on equity of -49.58% beat Cognition Therapeutics' return on equity.
43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 23.8% of Cognition Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cognition Therapeutics received 8 more outperform votes than JATT Acquisition when rated by MarketBeat users.
In the previous week, Cognition Therapeutics had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Cognition Therapeutics and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 beat Cognition Therapeutics' score of -0.75 indicating that JATT Acquisition is being referred to more favorably in the news media.
Cognition Therapeutics currently has a consensus target price of $6.67, suggesting a potential upside of 233.33%. Given Cognition Therapeutics' higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than JATT Acquisition.
Summary
Cognition Therapeutics and JATT Acquisition tied by winning 5 of the 10 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
